Twentyeight-Seven Therapeutics

Twentyeight-Seven Therapeutics, now operating as Redona Therapeutics, is a private biotechnology company based in Watertown, Massachusetts focused on discovering first-in-class small-molecule drugs against enzymes that regulate RNA and DNA processing and sensing. The company originated from Harvard-linked founding science in non-coding RNA biology and initially launched around modulation of microRNA pathways in cancer. Its current pipeline highlights preclinical programs against CDC-like kinases, TUT4/TUT7, and cGAS, spanning oncology, inflammation, autoimmune disease, and HBV. Redona positions itself as a platform-enabled discovery company with proprietary biochemical, cellular, chemical, and bioinformatic tools to interrogate nucleic acid-protein interactions and advance differentiated therapeutics toward the clinic.